Preparation and characterization of poly(lactic acid) nanoparticles for sustained release of pyridostigmine bromide

Pharmazie

Volumn 67, Issue 4, 2012, Pages 311-318

  Tan, Q Y ^a   Xu, M L ^b   Wu, J Y ^b   Yin, H F ^b   Zhang, Jingqing ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; POLYLACTIC ACID; PYRIDOSTIGMINE; CHOLINESTERASE INHIBITOR; DRUG CARRIER; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; LACTIC ACID; POLYMER;

ARTICLE; CONTROLLED STUDY; DIALYSIS; DRUG SOLUBILITY; IN VITRO STUDY; MULTIPLE LINEAR REGRESSION ANALYSIS; PARTICLE SIZE; PROCESS OPTIMIZATION; STATISTICAL SIGNIFICANCE; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ALGORITHM; CHEMISTRY; DELAYED RELEASE FORMULATION; ELECTROCHEMISTRY; REPRODUCIBILITY; SPECTROSCOPY; STATISTICAL MODEL; SYNTHESIS; ULTRAVIOLET SPECTROPHOTOMETRY;

ALGORITHMS; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; ELECTROCHEMISTRY; INDICATORS AND REAGENTS; LACTIC ACID; MODELS, STATISTICAL; NANOPARTICLES; PARTICLE SIZE; POLYMERS; PYRIDOSTIGMINE BROMIDE; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTRUM ANALYSIS;

EID: 84861733159     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1103     Document Type: Article

References (33)

1. Adair JH, Parette MP, Altinoǧlu EI, Kester M (2010) Nanoparticulate alternatives for drug delivery. ACS Nano 4: 4967-4970.
2. Andersen JB, Engeland A, Owe JF, Gilhus NE (2010) Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 17: 1445-1450.
3. Basarkar A, Devineni D, Palaniappan R, Singh J (2007) Preparation, characterization, cytotoxicity and transfection efficiency of poly(DL-lactide- co-glycolide) and poly(DL-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA. Int J Pharm 343: 247-254.
4. Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F (1985) Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin Pharmacol Ther 37: 495-501.
5. Chaisria W, Hennink WE, Okonogi S (2009) Preparation and characterization of cephalexin loaded PLGA microspheres. Curr Drug Deliv 6: 69-75.
6. Conte U, Genta I, Giunchedi P, Modena T (1995) Testing of 'in vitro' dissolution behaviour of microparticulate drug delivery systems. Drug Dev Ind Pharm 21: 1223-1233.
7. El-Gindy A, Emara S, Hadad GM (2004) Determination of certain drugs in binary mixtures formulations by second derivative ratio spectrophotometry and LC. Farmaco 59: 703-712.
8. Gonzalez-Mira E, Egea MA, Souto EB, Calpena AC, García ML (2011) Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology 22: 045101.
9. Hegazy N, Demirel M, Yazan Y (2002) Preparation and in vitro evaluation of pyridostigmine bromide microparticles. Int J Pharm 242: 171-174.
10. Hou ZQ, Zhou CX, Luo Y, Zhan CM,Wang YX, Xie LY, Zhang QQ (2011) PLA nanoparticles loaded with an active lactone form of hydroxycamptothecin: development, optimization,and in vitro-in vivo evaluation in mice bearing h22 solid tumor. Drug Dev Res 72: 1-9.
11. Huang YT, Tsai TR, Cheng CJ, Cham TM, Lai TF, Chuo WH (2007) Formulation design of an HPMC-based sustained release tablet for pyridostigmine bromide as a highly hygroscopic model drug and its in vivo/in vitro dissolution properties. Drug Dev Ind Pharm 33: 1183-1191.
12. Ishihara T, Takahashi M, Higaki M, Mizushima Y, Mizushima T (2010) Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents. Int J Pharm 385: 170-175.
13. Kouchakzadeh H, Shojaosadati SA, Maghsoudi A, Vasheghani FE (2010) Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology. AAPS PharmSciTech 11: 1206-1211.
14. Kumari A, Yadav SK, Pakade YB, Kumar V, Singh B, Chaudhary A, Yadav SC (2011) Nanoencapsulation and characterization of Albizia chinensis isolated antioxidant quercitrin on PLA nanoparticles. Colloids Surf B Biointerfaces. 82: 224-232.
15. Kunii R, Onishi H, Machida Y. (2007) Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur J Pharm Biopharm 67: 9-17.
16. Lan CH, Rémi F, Yves W (2011) Increase in stability and change in supramolecular structure of b-carotene through encapsulation into polylactic acid nanoparticles. Food Chem 124: 42-49.
17. Leo E, Brina B, Forni F, Vandelli MA (2004) In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. Int J Pharm 278: 133-41.
18. Liu J, Qiu Z,Wang S, Zhou L, Zhang S (2010) A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity. Biomed Mater 5: 065002.
19. Lu B, Zhang JQ Yang H (2003) Non phospholipid vesicles of carboplatin for lung targeting. Drug Deliver 10: 87-94.
20. Magenheim B, Levy MY, Benita S (1993) A new in vitro technique for evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int J Pharm 94: 115-123.
21. Martins SAM, Prazeres DMF, Fonseca LP, Monteiro GA (2009) Application of central composite design for DNA hybridization onto magnetic microparticles. Anal BioChem 391: 17-23.
22. Maselli RA, Henderson JD, Ng J, Follette D, Graves G.Wilson BW (2011) Protection of human muscle acetylcholinesterase from soman by pyridostigmine bromide. Muscle Nerve. 43: 591-595.
23. Musumeci T, Ventura CA, Giannone L, Ruozi B, Montenegro L, Pignatello R, Puglisi G (2006) PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 325: 172-179.
24. Nagarwal RC, Singh PN, Kant S, Maiti P, Pandit JK (2010) Chitosan coated PLA nanoparticles for ophthalmic delivery: characterization, in-vitro and in-vivo study in rabbit eye. J Biomed Nanotechnol 6: 648-657.
25. Nevarez L, Vasseur V, Debaets S, Barbier G (2010) Use of response surface methodology to optimise environmental stress conditions on Penicillium glabrum, a food spoilage mould. Fungal Biol 114: 490-497.
26. Rodenas V, Parra A, Garcia-Villanova J, Gomez MD (1995) Simultaneous determination of cefepime and L-arginine in injections by secondderivative spectrophotometry. J Pharm Biomed Anal 13: 1095-1099.
27. Román-Velázquez, CE, Noguez,C(2011) Designing the plasmonic response of shell nanoparticles: spectral representation. J Chem Phys 134: 044116.
28. Sieb JP, Köhler W (2010) Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: Results of a prospective multicenter openlabel trial. Clin Neurol Neurosurg 112: 781-784.
29. Tan QY, Wang N, Yang H, Chen L, Xiong HR, Zhang LK, Liu J, Zhao CJ, Zhang JQ (2010a) Preparation and characterization of lipid vesicles containing uricase. Drug Deliver 17: 28-37.
30. Tan QY, Wang N, Yang H, Zhang LK, Liu S, Chen L, Liu J, Zhang L, Hu NN, Zhao CJ, Zhang JQ (2010b) Characterization, stabilization and activity of uricase loaded in lipid vesicles. Int J Pharm 384: 165-172.
31. White MC, De Silva P, Havard CW (1981) Plasma pyridostigmine levels in myasthenia gravis. Neurology 31: 145-150.
32. Zhang JQ, Liu J, Li XL, Jasti BR (2007) Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv 14: 381-387.
33. Zhang JQ, Zhang ZR,Yang H, TanQY, Qing SR, QiuXL(2005) Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. Pharm Res 22: 573-583.